PE20151747A1 - Metodo para inhibir cataratas y presbicia - Google Patents

Metodo para inhibir cataratas y presbicia

Info

Publication number
PE20151747A1
PE20151747A1 PE2015001991A PE2015001991A PE20151747A1 PE 20151747 A1 PE20151747 A1 PE 20151747A1 PE 2015001991 A PE2015001991 A PE 2015001991A PE 2015001991 A PE2015001991 A PE 2015001991A PE 20151747 A1 PE20151747 A1 PE 20151747A1
Authority
PE
Peru
Prior art keywords
cataracts
inhibit
presbycia
presbyopia
crystallines
Prior art date
Application number
PE2015001991A
Other languages
English (en)
Inventor
Murugappan Muthukumar
Benjamin Mohr
Original Assignee
Univ Massachusetts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Massachusetts filed Critical Univ Massachusetts
Publication of PE20151747A1 publication Critical patent/PE20151747A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A61M37/0092—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin using ultrasonic, sonic or infrasonic vibrations, e.g. phonophoresis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/325—Applying electric currents by contact electrodes alternating or intermittent currents for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A61M2037/0007—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin having means for enhancing the permeation of substances through the epidermis, e.g. using suction or depression, electric or magnetic fields, sound waves or chemical agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Dermatology (AREA)
  • Medical Informatics (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Emergency Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Materials For Medical Uses (AREA)

Abstract

Se describen metodos para inhibir o revertir el avance de la formacion de cataratas o de la presbicia en un ojo, administrando un agente de enmascaramiento de carga de gamma-cristalinas. Tanto las presbicia como las cataratas se producen por la agregacion de las proteinas del cristalino solubles llamada cristalinas
PE2015001991A 2013-03-14 2014-03-14 Metodo para inhibir cataratas y presbicia PE20151747A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361782860P 2013-03-14 2013-03-14

Publications (1)

Publication Number Publication Date
PE20151747A1 true PE20151747A1 (es) 2015-12-18

Family

ID=50686164

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2015001991A PE20151747A1 (es) 2013-03-14 2014-03-14 Metodo para inhibir cataratas y presbicia

Country Status (20)

Country Link
US (3) US9789091B2 (es)
EP (1) EP2968239B1 (es)
JP (1) JP6397477B2 (es)
KR (1) KR102198622B1 (es)
CN (1) CN105209033B (es)
AU (1) AU2014236582B2 (es)
BR (1) BR112015023348B1 (es)
CA (1) CA2904657C (es)
CL (1) CL2015002689A1 (es)
CR (1) CR20150537A (es)
EA (1) EA029070B1 (es)
ES (1) ES2727293T3 (es)
HK (1) HK1218390A1 (es)
IL (1) IL241306B (es)
MX (1) MX366115B (es)
PE (1) PE20151747A1 (es)
SA (1) SA515361106B1 (es)
SG (1) SG11201507209SA (es)
WO (1) WO2014152818A1 (es)
ZA (1) ZA201506987B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2968239B1 (en) * 2013-03-14 2019-04-24 The University of Massachusetts Methods of inhibiting cataracts and presbyopia
EP3347368A4 (en) * 2015-09-08 2019-01-23 Viewpoint Therapeutics, Inc. COMPOUNDS AND FORMULATIONS FOR TREATING OPHTHALMIC DISEASES
EA035402B1 (ru) * 2015-11-13 2020-06-08 Зе Юниверсити Оф Массачусеттс Бифункциональные молекулы, содержащие полиэтиленгликоль, для подавления катаракт и пресбиопии
MX2021014682A (es) * 2019-05-31 2022-04-06 Plex Pharmaceuticals Inc Agentes farmacológicos para tratar enfermedades de agregación de proteínas de los ojos.
US11607064B2 (en) * 2019-08-06 2023-03-21 Dart Industries Inc. Reusable drinking straw
KR102587830B1 (ko) * 2021-07-22 2023-10-10 사회복지법인 삼성생명공익재단 딥러닝을 이용한 백내장 진단방법 및 시스템
US20230310380A1 (en) * 2022-04-05 2023-10-05 Alan Neil Glazier Methods, devices, and systems for treating lens protein aggregation diseases

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4526789A (en) 1980-02-29 1985-07-02 Massachusetts Institute Of Technology Process for preventing or reversing cataract formation
US4351826A (en) 1980-02-29 1982-09-28 Massachusetts Institute Of Technology Process for preventing or reversing cataract formation using acrylamides
US4665089A (en) 1985-03-21 1987-05-12 Massachusetts Institute Of Technology Process for preventing or reversing cataract formation using protein modification reagents
US4620979A (en) 1985-08-02 1986-11-04 Schachar Ronald A Ophthalmological irrigating solution containing ascorbate
US4771036A (en) 1986-02-10 1988-09-13 Trustees Of Columbia University In The City Of New York Method and ophthalmic composition for the prevention and reversal of cataracts
CA1269327A (en) 1986-04-24 1990-05-22 Massachusetts Institute Of Technology Process for preventing or reversing cataract formation using protein modification reagents
US5055291A (en) 1986-11-04 1991-10-08 Baylor College Of Medicine Compositions for preventing secondary cataracts
US4808182A (en) 1986-11-26 1989-02-28 Nestle, S.A. Deswelled, hydrogel intraocular lenses
US5091421A (en) 1987-06-04 1992-02-25 Massachusetts Institute Of Technology Chemical prevention or reversal of cataract by phase separation inhibitors
US5338545A (en) 1987-06-04 1994-08-16 Oculon Corporation Chemical prevention or reversal of cataract by phase separation inhibitors
US5614587A (en) * 1988-11-21 1997-03-25 Collagen Corporation Collagen-based bioadhesive compositions
DE3906311A1 (de) 1989-02-28 1990-08-30 Adatomed Pharma & Med Behandlungsystem zur verhinderung von nachstarbildung nach einer kataraktoperation
WO1992000748A1 (en) 1990-07-06 1992-01-23 Enzon, Inc. Poly(alkylene oxide) amino acid copolymers and drug carriers and charged copolymers based thereon
EP0489991B1 (en) 1990-12-10 1996-06-05 Bio-Physio Pharmaceutical Research And Development Company Limited Indeno-d-pyrimidone compounds for use in medicine
AU2147192A (en) 1991-06-28 1993-01-25 Genentech Inc. Method of stimulating immune response using growth hormone
CA2135302A1 (en) * 1992-05-20 1993-11-25 Mitsuyoshi Azuma Agent for treating cataract and method for its preparation
US5375611A (en) 1993-01-26 1994-12-27 Pharmacia Ab Method for preventing secondary cataract
CN1045383C (zh) 1993-04-07 1999-10-06 王慧康 用于治疗老年性白内障的药物组合物
US5663304A (en) 1993-08-20 1997-09-02 Genentech, Inc. Refolding of misfolded insulin-like growth factor-I
DE69434617D1 (de) 1993-11-19 2006-04-06 Univ Sydney Verfahren zur prophylaxe oder kontrolle des katarakts
US5516534A (en) 1993-11-26 1996-05-14 Rensselaer Polytechnic Institute Composition and method for reducing structural defects
US5591773A (en) 1994-03-14 1997-01-07 The Trustees Of Columbia University In The City Of New York Inhibition of cataract formation, diseases resulting from oxidative stress, and HIV replication by caffeic acid esters
US5658592A (en) 1994-05-13 1997-08-19 Kuraray Co., Ltd. Medical crosslinked polymer gel of carboxylic polysaccharide and diaminoalkane
DE69629230D1 (de) 1995-03-24 2003-09-04 Ocular Res Of Bonton Inc Hydrogellinse mit Lipid-Vorbeschichtigung
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
JP3599848B2 (ja) 1995-09-11 2004-12-08 株式会社メニコン 含水性軟質眼用レンズ用材料、それからなる含水性軟質眼用レンズ用成形体、ならびにそれからなる含水性軟質眼用レンズおよびその製法
EP0781777A1 (en) 1995-12-28 1997-07-02 Menicon Co., Ltd. Silicon-containing compound and ocular lens material
US5807944A (en) * 1996-06-27 1998-09-15 Ciba Vision Corporation Amphiphilic, segmented copolymer of controlled morphology and ophthalmic devices including contact lenses made therefrom
DE69714663T2 (de) 1996-06-28 2003-04-10 Ube Industries Verfahren zur Herstellung von Polybutadien
US5817630A (en) 1997-03-18 1998-10-06 Austin Nutriceutical Corporation Glutathione antioxidant eye drops
JPH10339857A (ja) 1997-06-05 1998-12-22 Menicon Co Ltd 薬剤徐放性コンタクトレンズの製法およびそれによってえられた薬剤徐放性コンタクトレンズ
US6015787A (en) 1997-11-04 2000-01-18 New England Medical Center Hospitals, Inc. Cell-permeable protein inhibitors of calpain
US6291466B1 (en) 1998-07-30 2001-09-18 Allergan Sales, Inc. Cholinergic agents in the treatment of presbyopia
EP1149909A1 (en) 2000-04-28 2001-10-31 Boehringer Mannheim Gmbh Methods for regulating protein conformation using molecular chaperones
US6103756A (en) 1999-08-11 2000-08-15 Vitacost Inc. Ocular orally ingested composition for prevention and treatment of individuals
CA2389917A1 (en) 1999-11-04 2001-05-10 Kazunori Kataoka A polymer micelle as monolayer or layer-laminated surface
US6835394B1 (en) 1999-12-14 2004-12-28 The Trustees Of The University Of Pennsylvania Polymersomes and related encapsulating membranes
US7977385B2 (en) 2000-03-02 2011-07-12 Numoda Biotechnologies, Inc. Agents for corneal or intrastromal administration to treat or prevent disorders of the eye
JP2003534383A (ja) 2000-05-31 2003-11-18 セラス コーポレイション 免疫原性が減少した赤血球の病原体不活性化溶液の調製
CA2434911C (en) 2000-12-15 2009-12-08 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A Use of l-carnitine as stabilizing agent of proteins
US6958224B2 (en) 2001-03-28 2005-10-25 Council Of Scientific And Industrial Research Chimeric protein α BNAC crystallin with extraordinarily high chaperone-like activity and a method related to the use thereof
US20030020870A1 (en) 2001-06-27 2003-01-30 Zms, Llc Biomedical molding materials from semi-solid precursors
US20040254197A1 (en) 2001-09-28 2004-12-16 Santen Pharmaceutical Co., Ltd. Injections for eye tissues containing drug bonded to polyethlene glycol
WO2003086305A2 (en) * 2002-04-10 2003-10-23 The Regents Of The University Of California Biodegradable peg-based polymer formulations in ocular applications
US6924154B2 (en) 2002-08-20 2005-08-02 Quest Diagnostics Investments Incorporated Hydrophilic chemilumescent acridinium labeling reagents
JP2004161731A (ja) 2002-09-25 2004-06-10 Nof Corp 生体関連物質用固定化剤
SG177008A1 (en) 2003-03-05 2012-01-30 Halozyme Inc Soluble hyaluronidase glycoprotein (shasegp), process for preparing the same, uses and pharmaceutical compositions comprising thereof
CN1621091A (zh) 2003-11-28 2005-06-01 付经国 聚乙二醇化轮状病毒体肠靶向制剂及其合成方法
WO2005076998A2 (en) 2004-02-05 2005-08-25 Intradigm Corporation Rnai therapeutics for treatment of eye neovascularization diseases
WO2005112977A2 (en) 2004-04-23 2005-12-01 Pharmain, Ltd. Compositions for treatment with glucagon-like peptide, and methods of making and using the same
WO2005110375A1 (en) 2004-05-08 2005-11-24 Paul Edward L Jr Nutritional supplement for treatment of ocular diseases
WO2005117987A1 (en) 2004-06-01 2005-12-15 Glazier Alan N Antibody conjugates targeting to ocular proteins
US6945971B1 (en) 2004-07-19 2005-09-20 Gwon Arlene E Controlled ocular lens regeneration
EP1814578A2 (en) * 2004-11-04 2007-08-08 University of Washington Compositions and methods for treatment of protein misfolding and protein aggregation diseases
US7741311B2 (en) * 2005-01-03 2010-06-22 Shaker Mousa Composition and method for treating occlusive vascular diseases, nerve regeneration, and wound healing
CN1660920A (zh) 2005-02-01 2005-08-31 华东理工大学 末端连接ω－氨基酸的聚乙二醇酸或活性酯及制法和应用
DE102005041570A1 (de) 2005-09-01 2007-03-22 Celares Gmbh Hoch verzweigte Reagenzien zur Modifaktion von Biopharmazeutika, deren Herstellung und Anwendung
US7832875B2 (en) 2005-09-29 2010-11-16 Virtek Vision International Inc. Modulated diode pumped microchip laser projector
US20080094573A1 (en) 2006-04-04 2008-04-24 Vermette Patrick Surface-modified materials, such as contact lenses, methods and kits for their preparation, and uses thereof
US20070275098A1 (en) 2006-05-19 2007-11-29 T.R.P. Company, Inc, A Nevada Corporation Formulation and methodology for the treatment for eye impairment symptoms
WO2008145721A2 (en) * 2007-06-01 2008-12-04 Novo Nordisk A/S N-terminal modification of polypeptides for protection against degradation by aminopeptidases
AU2008295449A1 (en) 2007-09-07 2009-03-12 Industrial Research Limited Agents with angiogenic and wound healing activity
JPWO2009051223A1 (ja) 2007-10-19 2011-03-03 株式会社アールテック・ウエノ 白内障処置のための医薬組成物
KR20100000203A (ko) 2008-06-24 2010-01-06 인하대학교 산학협력단 금나노입자를 이용한 표적지향형 항암약물전달체
CN102137654A (zh) 2008-06-30 2011-07-27 庄臣及庄臣视力保护公司 用于治疗眼过敏的方法和眼科装置
PT2300514E (pt) * 2008-07-14 2016-06-20 Biocon Ltd Um método de síntese de uma mistura substancialmente monodispersa de oligómeros
WO2010065024A1 (en) 2008-12-05 2010-06-10 Kador Peter F Topical treatment of cataracts in dogs
EP2398499B1 (en) * 2009-02-18 2017-09-06 Eyeon Particle Sciences LLC Bi-functional co-polymer use for ophthalmic and other topical and local applications
WO2010130638A1 (en) 2009-05-14 2010-11-18 Evotec Ag Sulfonamide compounds, pharmaceutical compositions and uses thereof
EP2512492A1 (en) 2009-12-14 2012-10-24 University of Massachusetts Methods of inhibiting cataracts and presbyopia
US20130084262A1 (en) 2010-04-19 2013-04-04 Andrea S. Gobin Repairing bruch's membrane with hydrogels
CA2930801C (en) 2010-11-05 2019-05-28 Rinat Neuroscience Corporation Engineered polypeptide conjugates and methods for making thereof using transglutaminase
CN102172410B (zh) 2011-01-14 2013-08-07 华南理工大学 用于癌症诊断与治疗的靶向纳米粒传输系统的构建方法
CN102634492B (zh) 2011-02-14 2015-06-10 重庆富进生物医药有限公司 聚乙二醇化犬源尿酸氧化酶类似物及其制备方法和应用
CN103918055B (zh) * 2011-03-31 2016-08-17 Dh科技发展私人贸易有限公司 用于校准质谱仪的组合物、方法和试剂盒
WO2012142659A1 (en) 2011-04-19 2012-10-26 Baker Idi Heart And Diabetes Institute Holdings Limited Site-selective modification of proteins
EP3366311B1 (en) 2011-06-03 2020-02-26 3M Innovative Properties Co. Hydrazino-1h-imidazoquinolin-4-amines and conjugates made therefrom
CN202172410U (zh) 2011-08-23 2012-03-21 东莞市铭普实业有限公司 一种基于物联网的带按键的射频智能光模块
US9441024B2 (en) 2011-09-04 2016-09-13 Glytech, Inc. Glycosylated polypeptide and drug composition containing said polypeptide
KR20140103099A (ko) 2011-10-12 2014-08-25 아센디스 파마 옵탈몰로지 디비젼 에이/에스 안구 병태의 예방 및 치료
CN102579353B (zh) 2012-03-30 2013-12-04 吉林大学 叶酸靶向的抗癌药物peg修饰的脂质体及制备方法
MX370543B (es) 2012-10-11 2019-12-17 Ascendis Pharma Ophthalmology Div A/S Profarmacos neutralizantes del factor de crecimiento endotelial vascular para el tratamiento de afecciones oculares.
WO2014071132A1 (en) 2012-11-01 2014-05-08 The Johns Hopkins University Contact lens surface modification with hyaluronic acid (ha) binding peptide for ha accumulation and retention
EP2968239B1 (en) 2013-03-14 2019-04-24 The University of Massachusetts Methods of inhibiting cataracts and presbyopia
WO2014171842A1 (en) 2013-04-19 2014-10-23 Living Cell Technologies New Zealand Limited Biocompatible encapsulation system
CN113274506A (zh) 2013-12-05 2021-08-20 念·吴 聚合物-碳水化合物的缀合物的药物转递技术
EA035402B1 (ru) 2015-11-13 2020-06-08 Зе Юниверсити Оф Массачусеттс Бифункциональные молекулы, содержащие полиэтиленгликоль, для подавления катаракт и пресбиопии

Also Published As

Publication number Publication date
ZA201506987B (en) 2016-12-21
JP6397477B2 (ja) 2018-09-26
HK1218390A1 (zh) 2017-02-17
US9789091B2 (en) 2017-10-17
CA2904657A1 (en) 2014-09-25
AU2014236582B2 (en) 2018-03-29
EA029070B1 (ru) 2018-02-28
CN105209033A (zh) 2015-12-30
SG11201507209SA (en) 2015-10-29
JP2016517428A (ja) 2016-06-16
ES2727293T3 (es) 2019-10-15
US20160074370A1 (en) 2016-03-17
KR20150130361A (ko) 2015-11-23
IL241306B (en) 2019-11-28
US20160000707A1 (en) 2016-01-07
MX2015013034A (es) 2016-07-05
US10413529B2 (en) 2019-09-17
BR112015023348B1 (pt) 2023-04-25
CN105209033B (zh) 2018-09-18
EP2968239A1 (en) 2016-01-20
CL2015002689A1 (es) 2016-02-05
BR112015023348A2 (pt) 2017-07-18
IL241306A0 (en) 2015-11-30
MX366115B (es) 2019-06-27
CA2904657C (en) 2021-02-16
SA515361106B1 (ar) 2018-09-25
WO2014152818A1 (en) 2014-09-25
EA201591677A1 (ru) 2016-01-29
AU2014236582A1 (en) 2015-11-05
EP2968239B1 (en) 2019-04-24
NZ713007A (en) 2020-11-27
US9675589B2 (en) 2017-06-13
CR20150537A (es) 2015-11-27
US20170231905A1 (en) 2017-08-17
KR102198622B1 (ko) 2021-01-05

Similar Documents

Publication Publication Date Title
PE20151747A1 (es) Metodo para inhibir cataratas y presbicia
EA201891186A1 (ru) Антитела, нейтрализующие вирус иммунодефицита человека
EA201890424A1 (ru) Получение клеток пигментного эпителия сетчатки
CR20170031A (es) Composiciones de portador-anticuerpo y métodos para realizarlas y utilizarlas
EA201791005A1 (ru) Улучшенные антитела против il-6
EA201692425A1 (ru) Модифицированные биополимеры и способы их получения и использования
EA201691194A1 (ru) Стимуляторы ргц
CO2017002506A2 (es) Nuevos activadores de la guanilato ciclasa soluble y su uso
AR091237A1 (es) Composiciones que comprenden un aptamero anti factor de crecimiento derivado de plaquetas (anti-pdgf) y un antagonista de factor de crecimiento de endotelio vascular (vegf)
IL244687A0 (en) Epinephrine-based ophthalmic preparations for intraocular administration and methods for their production
CL2015002210A1 (es) Conjugados de ciclosporina a y esteroide
HK1216236A1 (zh) 給藥於眼後段的眼用製劑
EA201890442A1 (ru) Получение фоторецепторов для лечения заболеваний сетчатки
CO2017012573A2 (es) Formación de nanopartículas de ciclosporina a/ciclodextrina
BR112018009225A2 (pt) conjugados de anticorpo anti-cd22-maitansina e métodos de uso dos mesmos
CY1121000T1 (el) Sirna και χρηση αυτου σε μεθοδους και συνθεσεις για την θεραπεια ή/και προληψη οφθαλμικων καταστασεων
ES2538551R2 (es) Composición Oftálmica para la corrección de la presbicia
EP3503873A4 (en) EPINEPHRINE-BASED OPHTHALMIC COMPOSITIONS FOR INTRAOCULAR ADMINISTRATION AND METHOD FOR THE PRODUCTION THEREOF
EA201690075A1 (ru) Способ лечения внутриклеточной инфекции
BR112014020424A2 (pt) ponta de fragmentação, dispositio de cirurgia intra-ocular fornecido com as mesmas, método para suprimir ocorrência de cavitação e método de cirurgia de catarata
TR201902864T4 (tr) Beta-klorosiklopentanların hidrofilik ester ön ilaçlarının kullanımı ile azaltılmış merkezi korneal kalınlaşma.
CO2017002963A2 (es) Espiro-tiazolonas
UA116485U (uk) Cпосіб лектинохімічного дослідження
TR201715422A2 (tr) Bi̇r vaji̇nal i̇mplant
RU2015122200A (ru) Способ дифференциальной диагностики аутоиммунных и аллергических заболеваний

Legal Events

Date Code Title Description
FG Grant, registration